Wepox Safe 5000IU Injection contains Recombinant Human Erythropoietin Alfa, a glycoprotein hormone analog used to stimulate erythropoiesis, the production of red blood cells. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not yet on dialysis. Additionally, it is utilized in anemia management in patients undergoing chemotherapy for non-myeloid malignancies and in certain cases of HIV-infected patients receiving zidovudine therapy. Wepox Safe 5000IU acts by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation, thereby increasing hemoglobin levels and reducing the need for blood transfusions. The injection should be administered subcutaneously or intravenously as per the prescribing physician’s instructions, with dosage individualized based on patient response and hemoglobin targets. Monitoring of hemoglobin, hematocrit, and iron status is essential during therapy to optimize efficacy and minimize risks such as hypertension, thromboembolic events, and pure red cell aplasia. Wepox Safe 5000IU Injection should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Proper storage and handling as per guidelines are recommended to maintain product stability and efficacy.